• No results found

Health Care Inspecto~~rte -Pharmaceutical Affairs and Medical Technology

N/A
N/A
Protected

Academic year: 2022

Share "Health Care Inspecto~~rte -Pharmaceutical Affairs and Medical Technology"

Copied!
3
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Health Care Inspecto~~rte -Pharmaceutical Affairs and Medical Technology

CERTIFICATE NUMBER: NL/H 16/1009415

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER ~ ' z

Part 1

Issued following an inspection in accordance with Art. 15 of Directive 2001/20/EC

The competent authority of Netherlands confirms the following:

The manufacturer: Academisch Zieke~ahuis Leiden

Site address: Albintrsrlreef 2 (LO), LEIDEN, 2333ZA, Netherlands

Has been inspected under the national inspection programme in connection with manufacturing

authorisation no. 4576 F in accordance with Art. 13 of Directive 2001/20/EC h~ansposed in the following national legislation:

Art. 100 of the Medicines Act

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 2016-10-06 , it is considered that it complies with

• The principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC j This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk

management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

~ The certificate i•eferrec! lo in paragraph 111(5) ojDirectire 1001/83/EC and 80(SJ of Directive 2001/82/EC, sJtall also be required for i~npor(s coming fi•onr third coarnh•ies into a DLeniber State.

Z Guida~rce orr the inte~pretatiorr of dais template cn~f be joomd i~1 t)re He(p nrentr of EudrnGhlDP database.

j These r•equirenrents fulfil the GDLP reconrnierrdations of IVHO.

Online EudraGMDP, Ref key: 40351 Issuance Date: 2017-03-01 Signatory: Ms. M. v. d. Meulen Page 1 of 3 'w,~

(2)

Part 2 ~

Human Investigational Medicinal Products

1 MANUFACTURING OPERATIONS

1.1 Sterile products

1.1.2 Tei~mif~ally Sterilised (processing opei~atioi~s for tl~e folloti>>ing dosage forms) 1.1.2.1 Large volume liquids

1.1.2.3 Small volume liquids

1.1.3 Batch certification

1.2 Non-sterile products

1.2.1 Non-sterile p~•oducts (processing operations for the following dosage forms) 1.2.1.1 Capsules, hard shell

Special Requirements

7 Other: Prostaglandines/Cytokines(en) 1.2.1.5 Liquids for external use

1.2.1.6 Liquids for internal use Special Requirements

7 Other: including Testosteron liquids(en) 1.2.1.11 Semi-solids

1.2.1.12 Suppositories 1.2.1.13 Tablets

1.2.2 Batch certification

1.5 Packaging

1.5.1 Pf~ima~y Packing

1.5.1.1 Capsules, hard shell 1.5.1.5 Liquids for external use 1.5.1.6 Liquids for internal use 1.5.1.8 Other solid dosage forms 1.5.1.11 Semi-solids

1.5.1.12 Suppositories 1.5.1.13 Tablets

1.5.2 Secondary packing

1.6 Quality control testing

1.6.2 Microbiological: non-sterility 1.6.3 Chemical/Physical

1.6.E Biological

Online EudraGMDP, Rei key: 40351 Issuance Date: 2017-03-01 Signatory: Ms. M. v. d. Meulen Page 2 of 3~j -~

(3)

2 IMPORTATION OF MEDICINAL PR S

2.1 Quality control testing of imported medicinal products 2.1.2 Mic~~obiological: non-sterility

2.1.3 Chemical/Physical 2.1.4 Biological

2.2 Batch certification of imported medicinal products 2.2.1 Sterile proclarcts

2.2.1.1 Aseptically prepared 2.2.1.2 Terminally sterilised

2.2.2 Non-sterile products

2.2.3 Biological medicinal prodarcts 2.2.3.1 Blood products

2.2.3.2 Immunological products 2.2.3.3 Cell therapy products 2.2.3.4 Gene therapy products 2.2.3.5 Biotechnology products

2.2.3.6 Human or animal extracted products

2.3 Other importation activities

2.3.2 bnpo~~tation of intermediate tivlziclz zrncle~•goes fin•ther processing

2017-03-01 Ot d~ ~ea~~0~►

~t

o~~Q o~etheid R~~o~ ~/~

~ NO

~ v ~

3 ~ -+

d ~ ~ dq

G

' °' o~~

`q a~3

G~2 P~aa, y~J~

a~~//o/~ uenava~

Name and signature of the authorised person of the Competent Authority of Netherlands

~~'

Ms. Mieke vnn der Merrle~r

Henitl: Care Ltspectorate - Phar~nacerrtic~rl Affairs nfrd Medicnl Tedtnology

Tel: +31 881205000 Fax: +31 881205001

Online EudraGMDP, Rei key: 40351 Issuance Date: 2017-03-01 Signatory: Ms. M. v. d. Meulen Page 3 of 3 f?`7

Referenties

GERELATEERDE DOCUMENTEN

De voedselkwaliteit (het gehalte chlorofyl gedeeld door het gehalte aan zwevende stof) is mede bepalend voor de conditie van de schelpdieren: een hogere kwaliteit resulteert in

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of

De aanzienlijke vorderingen die geboekt zijn bij het wegnemen van deze beperkende factoren hebben ender meer in de USA en de BRD qeresulteerd in aanbevelingen

An increase in the world prices of exports and imports, due to the liberalisation of the food and agricultural commodity trade of the OECD countries, will likely benefit the

Using one sample of 19 manufacturing firms and another sample of 23 non-manufacturing firms over a period from 2000 to 2007, I test whether psychic distance in

It could also be the case that the hypothesised channel is of insufficient magnitude: despite finding a significant positive relationship between aid and the channel of real

Is considered to be part of the personnel viewpoint, for convenience reasons.. from them by analysis techniques. At the moment, combining or integrating existing data and

Voor het Lagekostenbedrijf zijn al uitgebreide berekeningen gedaan om te zien in hoeverre het mogelijk is om al het mengvoer te vervangen door (natte) bijproducten.. Hieruit blijkt